2025 Telehealth Ketamine Laws: What Changed

The regulatory environment for telehealth ketamine continues to evolve rapidly. Understanding what changed entering 2025—and what developments are still in motion—is important for both patients relying on telehealth access and providers building sustainable practices.

DEA Telemedicine Prescribing Flexibilities: Current Status

The DEA telemedicine prescribing flexibilities—which allow Schedule II-V controlled substances to be prescribed via telehealth without a prior in-person visit—have been extended multiple times since the COVID public health emergency ended in May 2023. Our DEA compliance guide covers the current prescribing requirements in detail.

As of January 2025, the DEA's extended flexibilities remain in effect. The DEA has committed to maintaining these flexibilities while it finalizes permanent rulemaking for a telemedicine controlled substance prescribing framework. Providers operating under these extensions should:

• Continue documenting that prescriptions are issued pursuant to the applicable DEA extension
• Monitor DEA announcements closely, as the extension status can change
• Begin preparing for operating under permanent rules when they are finalized

The timeline for permanent rules remained uncertain entering 2025. The DEA withdrew its controversial 2023 proposed rules for revision after unprecedented public comment volume, and the rulemaking process restarted.

What the Permanent Rules Are Expected to Address

Based on the 2023 proposed rules and subsequent DEA communications, the permanent telemedicine prescribing framework is expected to include some version of the following:

Special Registration for Telemedicine Prescribing

Practitioners who want to prescribe controlled substances via telemedicine without a prior in-person visit will likely need to obtain a special DEA registration. This registration is expected to have:

• Eligibility requirements (practitioner type, licensure, specialty)
• Ongoing requirements (PDMP compliance, identity verification, record-keeping)
• Potentially, limits on prescribable drugs or conditions

Patient Identity Verification

The proposed rules included requirements for patient identity verification before controlled substance prescribing via telemedicine. Acceptable forms of verification were expected to include government-issued photo ID.

Prescription Quantity Limits

The 2023 proposals included a 30-day supply limit for initial telemedicine prescriptions and a requirement for in-person evaluation before continuation. These provisions were heavily criticized and may be modified in the revised rules.

PDMP Compliance

PDMP checking before controlled substance prescribing, already required in most states, is expected to be explicitly incorporated into the federal framework.

Notable State-Level Developments in 2024-2025

States Updating Telehealth Practice Standards

Several states enacted or updated telehealth practice standards in 2024. Trends include:

• Codifying telemedicine prescribing standards into state law (rather than relying solely on state board guidance)
• Expanding interstate licensing compact participation
• Updating PDMP requirements to include telehealth-specific provisions

State Compact Expansion

The Interstate Medical Licensure Compact, Nurse Licensure Compact, and Physician Assistant Licensure Compact all added member states in 2024. As of early 2025, the IMLC covers over 40 states, significantly expanding the geographic reach of telehealth prescribers.

State-Specific Restrictions

A small number of states enacted or considered legislation restricting telehealth prescribing of controlled substances beyond federal requirements. These state-specific restrictions affect whether certain telehealth platforms can operate in those states even when federal exemptions apply.

The Spravato (Esketamine) Regulatory Distinction

While compounded ketamine for at-home telehealth remains off-label, the FDA-approved esketamine nasal spray (Spravato) continues to operate under its own distinct regulatory pathway. In 2024, the FDA added new data to the Spravato label and the REMS program was updated. Spravato remains a certified healthcare setting-only treatment—it is administered in clinics with 2-hour post-dose monitoring, not at home.

This regulatory distinction is important: Spravato's FDA approval and REMS requirements are entirely separate from the DEA telemedicine prescribing framework that governs at-home compounded ketamine. They are different products, different legal frameworks, and different clinical models. For a side-by-side comparison, see our generic ketamine vs. Spravato guide.

Congressional Activity

Congress continued in 2024-2025 to consider legislation related to telehealth and controlled substance prescribing. Key areas of legislative interest:

• Permanent codification of some COVID-era telehealth flexibilities
• Congressional direction to the DEA on the special registration framework timeline
• The Telehealth Modernization Act and similar proposals to standardize interstate telehealth practice

None of these legislative efforts had reached enactment as of early 2025, but Congressional interest in the issue was sustained and bipartisan.

What This Means for Patients in 2025

Access is currently maintained. As of early 2025, telehealth ketamine access continues under the extended DEA flexibilities. Patients should be able to access existing platforms without disruption.

The picture may change. When permanent DEA rules are finalized—likely in 2025 or 2026—there may be operational changes for telehealth platforms. Some may need to obtain special registrations. Some protocols may need adjustment. The direction of the permanent rules will determine the magnitude of change.

Geographic access is expanding. Continued growth of interstate licensing compacts means more telehealth providers can serve more states.

Stay informed. Patients who rely on telehealth ketamine should follow DEA rulemaking and their platform's communications about regulatory compliance. This is a rapidly evolving area where significant changes are possible within a 12-24 month horizon.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service